Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 11Neoplasms 4Stomach Neoplasms 2Small Cell Lung Carcinoma 2Metastatic Pancreatic Adenocarcinoma 2Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor 1Refractory Solid Tumors 1Pancreatic cancer, adult 1Pancreatic Diseases 1Pancreatic Cancer Non-resectable 1Ovarian Neoplasms 1Neoplasm Metastasis 1Metastatic Adenocarcinoma of the Pancreas 1Malignant Tumor of Pancreas Metastatic to Liver 1Head and Neck Neoplasms 1Gallbladder Neoplasms 1Endocrine Gland Neoplasms 1Digestive System Neoplasms 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Pancreatic Ductal 1Carcinoma, Islet Cell 1Biliary Tract Neoplasms 1Advanced Solid Tumors 1Advanced Pancreatic Cancer 1Advanced Esophageal Squamous Cell Cancer 1Advanced Breast Cancer 1Adenoma, Islet Cell 1

Interventions

Gemcitabine 3Leucovorin 2Fluorouracil 2pamrevlumab 1irinotecan sucrosofate 1folfirinox 1Taxes 1Oxaliplatin 1Irinotecan 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pancreatic Cancer Non-resectable × irinotecan sucrosofate × Clear all
NCT05047991 2021-09-17

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 2 Unknown
153 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡